Drug intelligence / Profile preview

NCB-0846

Development stage: Preclinical
Lead developer: Carna Biosciences
Modality: Small Molecules
Administration: Oral

Overview

NCB-0846 is an orally available small-molecule inhibitor of TRAF2- and NCK-interacting kinase (TNIK), a key component of the Wnt/β-catenin signaling pathway. Developed by Carna Biosciences, it binds to TNIK with high affinity (IC50 of 21 nM) and disrupts the formation of the TCF4/β-catenin transcriptional complex, thereby suppressing the expression of Wnt target genes. Preclinical studies have demonstrated its efficacy in inhibiting the growth of colorectal cancer stem cells and preventing metastasis in lung cancer models. Beyond oncology, NCB-0846 has shown potential in treating liver fibrosis and epilepsy, and acting as a radiosensitizer in lung squamous cell carcinoma.

Other names: cis-4-[[2-(1H-Benzimidazol-6-ylamino)-8-quinazolinyl]oxy]-cyclohexanol

Targets

TNIK (TRAF2- and NCK-interacting kinase)

Beyond the preview

Go deeper on NCB-0846.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCB-0846.

Explore the full profile